These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 23964810)
1. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Chilton M; Dunkley A; Carter P; Davies MJ; Khunti K; Gray LJ Diabetes Obes Metab; 2014 Mar; 16(3):237-47. PubMed ID: 23964810 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
4. Long-term effects of weight-reducing drugs in people with hypertension. Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640 [TBL] [Abstract][Full Text] [Related]
5. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442 [TBL] [Abstract][Full Text] [Related]
7. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Aydin N; Topsever P; Kaya A; Karasakal M; Duman C; Dağar A Tohoku J Exp Med; 2004 Mar; 202(3):173-80. PubMed ID: 15065643 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Viner RM; Hsia Y; Tomsic T; Wong IC Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432 [TBL] [Abstract][Full Text] [Related]
9. Drug interventions for the treatment of obesity in children and adolescents. Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001 [TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Derosa G; Mugellini A; Ciccarelli L; Fogari R Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711 [TBL] [Abstract][Full Text] [Related]
13. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
14. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013 [TBL] [Abstract][Full Text] [Related]
15. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Halpern B; Halpern A Expert Opin Drug Saf; 2015 Feb; 14(2):305-15. PubMed ID: 25563411 [TBL] [Abstract][Full Text] [Related]